Cover Image
市場調查報告書

大腸炎:開發平台分析

Colitis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232843
出版日期 內容資訊 英文 94 Pages
訂單完成後即時交付
價格
Back to Top
大腸炎:開發平台分析 Colitis - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 94 Pages
簡介

大腸炎是大腸的發炎,由病毒、寄生蟲、食物中毒(細菌)等感染,有過去大腸的發炎性疾病(潰瘍性大腸炎、克隆氏症 )、血流的不足(缺血性大腸炎)等各種原因。腹痛,腹脹,血便,發冷,脫水,腹瀉,有發熱等症狀,非類固醇消炎劑(NSAID),皮質類固醇等治療方法處於。

本報告以全球大腸炎治療藥的開發平台為主題,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等,為您概述為以下內容。

目錄

簡介

  • 調查範圍

大腸炎概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

各企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

在企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • Aerpio Therapeutics, Inc.
  • Ajinomoto製藥
  • Akebia Therapeutics, Inc.
  • Amorepacific Corporation
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Dr. Falk Pharma GmbH
  • Galapagos NV
  • Immuron Limited
  • Innate Pharma S.A.
  • Peptinov SAS
  • Pfizer Inc.
  • Prokarium Limited
  • Protalix BioTherapeutics, Inc.
  • RDD Pharma Ltd.
  • Saniona AB
  • Synovo GmbH

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AcTMP-1
  • AKB-4924
  • AKB-6899
  • AN-346
  • 腫瘤治療用肝素酶阻礙抗體
  • 大腸炎治療用抗體
  • 發炎性疾病、大腸炎治療用TNF Alpha阻礙反義RNAi寡核甘酸
  • APY-0201
  • BC-1215
  • BMS-986104
  • budesonide
  • 困難腸梭菌、疫苗
  • CSY-0073
  • 發炎性疾病、大腸炎治療用TRP 流通管道拮抗劑
  • etanercept biosimilar
  • filgotinib
  • IMM-124E
  • IPH-33
  • mesalamine
  • NK-007
  • PAC-14028
  • Peptide to Inhibit NFkB 大腸炎、腸炎治療用
  • PF-06425090
  • PPV-06
  • RDD-2007
  • 克隆氏症、大腸炎治療用 TNF-Alpha阻礙重組蛋白品質
  • 大腸炎治療藥
  • 大腸炎治療用 Panx1阻礙合成肽
  • 大腸炎治療用白細胞介素12/23標的疫苗
  • 大腸炎治療用白細胞介素23標的疫苗
  • ZK-216348

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8965IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H1 2017, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 18 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Colitis - Overview
  • Colitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Colitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Colitis - Companies Involved in Therapeutics Development
    • Akebia Therapeutics Inc
    • Bristol-Myers Squibb Company
    • Concenter BioPharma Silkim Ltd
    • Cosmo Pharmaceuticals NV
    • CSA Biotechnologies LLC
    • Dr. Falk Pharma GmbH
    • EA Pharma Co Ltd
    • Genfit SA
    • Immuron Ltd
    • Innate Pharma SA
    • Ogeda SA
    • Peptinov SAS
    • Pfizer Inc
    • RDD Pharma Ltd
    • Saniona AB
    • Sigmoid Pharma Ltd
    • Soligenix Inc
    • Synovo GmbH
  • Colitis - Drug Profiles
    • AcTMP-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AKB-6899 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AN-346 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody for Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APY-0201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BC-1215 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • budesonide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSA-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSY-0073 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dimethyloxalylglycine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dusquetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elafibranor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ESN-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMM-124E - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPH-33 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NK-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06425090 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PPV-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RDD-2007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rifamycin CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-182 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Crohn's Disease and Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit Panx1 for Colitis and Inflammatory Bowel Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPC-1022 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target IL12 and IL23 for Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target IL23 for Colitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Colitis - Dormant Projects
  • Colitis - Discontinued Products
  • Colitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Colitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Colitis - Pipeline by Akebia Therapeutics Inc, H1 2017
  • Colitis - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Colitis - Pipeline by Concenter BioPharma Silkim Ltd, H1 2017
  • Colitis - Pipeline by Cosmo Pharmaceuticals NV, H1 2017
  • Colitis - Pipeline by CSA Biotechnologies LLC, H1 2017
  • Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2017
  • Colitis - Pipeline by EA Pharma Co Ltd, H1 2017
  • Colitis - Pipeline by Genfit SA, H1 2017
  • Colitis - Pipeline by Immuron Ltd, H1 2017
  • Colitis - Pipeline by Innate Pharma SA, H1 2017
  • Colitis - Pipeline by Ogeda SA, H1 2017
  • Colitis - Pipeline by Peptinov SAS, H1 2017
  • Colitis - Pipeline by Pfizer Inc, H1 2017
  • Colitis - Pipeline by RDD Pharma Ltd, H1 2017
  • Colitis - Pipeline by Saniona AB, H1 2017
  • Colitis - Pipeline by Sigmoid Pharma Ltd, H1 2017
  • Colitis - Pipeline by Soligenix Inc, H1 2017
  • Colitis - Pipeline by Synovo GmbH, H1 2017
  • Colitis - Dormant Projects, H1 2017
  • Colitis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Colitis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Colitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top